Table 6. Two additional studies identified in systematic review of metformin and PCa risk and outcomes.

Author, year, country	Study design	No of patients	Main findings	Adjusted for
Haring, Finland, 2017 [75]	Cohort	78,615	Metformin decreased PCa incidence in a dose dependent manner (HR 0.81, 95%CI 0.69–0.95)	Age, trial arm, medications
Haggstrom, Sweden, 2017 [74]	Cohort	612,846	Metformin did not decrease PCa incidence (HR 0.96 95%CI 0.77–1.19)	Age, education, CCI, county